PDL chief resigns in wake of investor wrangle

Another biotech CEO bites the dust after tangling with a key investor. PDL BioPharma's CEO has decided to step aside after a company probe cleared him of charges leveled by the biotech's biggest shareholder. Mark McDade says he will leave by the end of this year, following a bitter fight with Third Point, which claimed the CEO had dropped the ball on a big deal with a major pharma company, missed projections and bungled the company's finances. The company's finance committee, though, concluded that there was no merit to Third Point's claims. Analysts generally applauded the planned exit, which triggered a surge in PDL's shares.

- check out the announcement on McDade's resignation
- here's the report on PDL from Forbes

Related Articles:
Biotech CEOs face rising fury of angry investors. Report
PDL BioPharma rises on shareholder complaint. Report
PDL therapy fails endpoints in Phase III. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.